‘Striking’ potential for ctDNA as a prognostic for melanoma outcomes

Circulating tumor DNA levels a few weeks after immunotherapy initiation could help identify patients with melanoma at greatest risk for recurrence or death.
A retrospective analysis showed individuals who had decreases in ctDNA levels from baseline had more than 30 times the likelihood of achieving disease control, 20-times greater odds of having an objective response, more than an 80% improvement in PFS and 70% improvement in OS compared with those who had increased ctDNA levels.
“Those were striking differences at a very early time point,” Vincent T. Ma, MD, assistant professor in the

Exercise during chemotherapy supports physical and cognitive health

​Researchers recommended a tailored, scientifically validated exercise program to individuals receiving chemotherapy for cancer, and those who were on a two-week chemotherapy schedule and followed the exercise prescription were able to maintain their walking-step goals, use resistance bands, and stay mentally sharper compared to patients who did not exercise.

Updated EULAR recommendations guide treatment decisions for rheumatoid arthritis

First published in 2010, the EULAR recommendations for the management of RA, the most frequent inflammatory rheumatic disease, have been relied upon by healthcare professionals and organisations worldwide to offer an up-to-date and robust analysis of the effectiveness and practical use of available DMARDs – from conventional agents such as methotrexate to biologics and Janus kinase (JAK) inhibitors.